A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)

Summary

A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease

Eligibility

Age range

55–85 years

Sex

All

Healthy volunteers

No

Interventions

• Drug
  Obicetrapib 10 mg

  once daily 10 mg Obicetrapib tablet

• Drug
  Matching placebo tablets

  matching placebo tablet

Location